Plantable Health Inc. (PLBL.NE)
| Previous Close | 0.0050 |
| Open | 0.0050 |
| Bid | 0.0050 x N/A |
| Ask | 0.0100 x N/A |
| Day's Range | 0.0050 - 0.0050 |
| 52 Week Range | 0.0050 - 0.4400 |
| Volume | |
| Avg. Volume | 147,009 |
| Market Cap | 632,500 |
| Beta (5Y Monthly) | N/A |
| PE Ratio (TTM) | N/A |
| EPS (TTM) | -0.1260 |
| Earnings Date | N/A |
| Forward Dividend & Yield | N/A (N/A) |
| Ex-Dividend Date | N/A |
| 1y Target Est | N/A |
- Newsfile
Plantable Health Inc. Reports Third Quarter Financial Results
New York, New York--(Newsfile Corp. - November 10, 2022) - Plantable Health Inc. (NEO: PLBL) (OTCQB: PLBLF) ("Plantable" or the "Company"), provides a clinically proven dietary intervention program to reverse and prevent chronic disease, today reported the financial results for the third quarter ended September 30, 2022. "Food as Medicine is now here. The recent White House announcement of their support of insurance coverage for dietary lifestyle interventions, including Food as Medicine, paves
- Newsfile
Plantable Health Announces U.S. Distribution Partnership with CookUnity, Bringing Plantable's Nutrient Dense Meals to a Wider Audience
New York, New York--(Newsfile Corp. - October 25, 2022) - Plantable® Health Inc. (NEO: PLBL) (OTCQB: PLBLF) ("Plantable" or the "Company") today announces it has entered into a new distribution agreement with CookUnity, a Brooklyn-based chef-to-eater marketplace, to distribute Plantable's fresh meals across the East Coast, with future expansion to the rest of the United States. This agreement represents a significant milestone for Plantable. CookUnity is the first chef-to-eater meal subscription
- Newsfile
Plantable Health Announces the Opening of a New Multi-Center Clinical Trial with Memorial Sloan Kettering Cancer Center
New York, New York--(Newsfile Corp. - October 18, 2022) - Plantable® Health Inc. (NEO: PLBL) (OTCQB: PLBLF) ("Plantable" or the "Company") today announces the opening of a new Clinical Trial, NUTRIVENTION-3, at Memorial Sloan Kettering Cancer Center (MSK) in New York, New York with Dr. Urvi Shah as Principal Investigator. This trial follows on the back of the promising recently presented preliminary results for NUTRIVENTION study (NCT04920084). The primary objective for this trial is ...
